ProBioGen AG
Katharina Vogdt has a diverse work experience in the fields of life sciences and research. Katharina began their career as a Masterstudent at Universität Potsdam in 2010, and then moved on to work as a PhD Student at Robert Koch Institute, FG18 HIV and Other Retroviruses from 2013 to 2016.
Since 2016, Katharina has been working at ProBioGen AG, where they have held two roles. Katharina started as a Project Leader Viral Vaccines Development and later became the Head of Vector Processes. Currently, they are still actively working in their position at ProBioGen AG as the Head of Vector Processes.
Overall, Katharina Vogdt has demonstrated a strong commitment to their field and a progression in their responsibilities and roles throughout their career.
Katharina Vogdt began their education in 2006 at Hamburg University of Applied Sciences, where they pursued a Bachelor of Science degree in Biotechnologie. Katharina dedicated five years to this program, completing it in 2011. Following their undergraduate studies, Katharina went on to enroll at the University of Potsdam in 2011, where they pursued a Master of Science degree in Biochemie und Molekularbiologie. Katharina successfully completed their master's program in 2013.
ProBioGen AG
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines. Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon. With over 25 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end.